Build Your Comparison

Side-by-side financial analysis
TOI logo
TOI
OPCH logo
OPCH
MCK logo
MCK
CAH logo
CAH
CVS logo
CVS
Try popular comparisons:

Stock Comparison

TOI vs OPCH vs MCK vs CAH vs CVS

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
TOI
The Oncology Institute, Inc.

Medical - Care Facilities

HealthcareNASDAQ • US
Market Cap$5.41B
5Y Perf.-47.2%
OPCH
Option Care Health, Inc.

Medical - Care Facilities

HealthcareNASDAQ • US
Market Cap$3.25B
5Y Perf.+49.6%
MCK
McKesson Corporation

Medical - Distribution

HealthcareNYSE • US
Market Cap$94.25B
5Y Perf.+411.0%
CAH
Cardinal Health, Inc.

Medical - Distribution

HealthcareNYSE • US
Market Cap$52.68B
5Y Perf.+328.9%
CVS
CVS Health Corporation

Medical - Healthcare Plans

HealthcareNYSE • US
Market Cap$130.09B
5Y Perf.+56.9%

TOI vs OPCH vs MCK vs CAH vs CVS — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
TOI logoTOI
OPCH logoOPCH
MCK logoMCK
CAH logoCAH
CVS logoCVS
IndustryMedical - Care FacilitiesMedical - Care FacilitiesMedical - DistributionMedical - DistributionMedical - Healthcare Plans
Market Cap$5.41B$3.25B$94.25B$52.68B$130.09B
Revenue (TTM)$546M$5.67B$403.43B$250.55B$407.90B
Net Income (TTM)$-44M$206M$4.76B$1.56B$2.93B
Gross Margin14.8%18.0%3.6%3.7%13.9%
Operating Margin-6.0%5.9%1.6%0.9%1.5%
Forward P/E11.3x17.7x20.8x13.8x
Total Debt$104M$0.00$8.61B$9.35B$93.59B
Cash & Equiv.$34M$233M$3.98B$3.87B$8.51B

TOI vs OPCH vs MCK vs CAH vs CVSLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

TOI
OPCH
MCK
CAH
CVS
StockJun 20Jun 26Return
The Oncology Instit… (TOI)10052.8-47.2%
Option Care Health,… (OPCH)100149.6+49.6%
McKesson Corporation (MCK)100511.0+411.0%
Cardinal Health, In… (CAH)100428.9+328.9%
CVS Health Corporat… (CVS)100156.9+56.9%

Price return only. Dividends and distributions are not included.

Quick Verdict: TOI vs OPCH vs MCK vs CAH vs CVS

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: OPCH leads in 3 of 7 categories (5-stock set), making it the strongest pick for valuation and capital efficiency and profitability and margin quality. The Oncology Institute, Inc. is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. CVS also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
🥇OPCH emerged as the overall leader. Track its performance:
TOI
The Oncology Institute, Inc.
The Growth Play

TOI is the #2 pick in this set and the best alternative if growth exposure is your priority.

  • Rev growth 27.8%, EPS growth 23.9%, 3Y rev CAGR 25.8%
  • 27.8% revenue growth vs CAH's -1.9%
  • +100.4% vs OPCH's -34.9%
Best for: growth exposure
OPCH
Option Care Health, Inc.
The Value Play

OPCH carries the broadest edge in this set and is the clearest fit for value and quality.

  • Lower P/E (11.3x vs 13.8x)
  • 3.6% margin vs TOI's -8.0%
  • 6.0% ROA vs TOI's -26.5%, ROIC 15.3% vs -41.2%
Best for: value and quality
MCK
McKesson Corporation
The Long-Run Compounder

MCK is the clearest fit if your priority is long-term compounding.

  • 337.8% 10Y total return vs CAH's 211.1%
Best for: long-term compounding
CAH
Cardinal Health, Inc.
The Lower-Volatility Pick

Among these 5 stocks, CAH doesn't own a clear edge in any measured category.

Best for: healthcare exposure
CVS
CVS Health Corporation
The Insurance Pick

CVS ranks third and is worth considering specifically for income & stability and sleep-well-at-night.

  • Dividend streak 0 yrs, beta 0.19, yield 2.6%
  • Lower volatility, beta 0.19, current ratio 0.84x
  • Beta 0.19, yield 2.6%, current ratio 0.84x
  • Beta 0.19 vs TOI's 1.95
Best for: income & stability and sleep-well-at-night
See the full category breakdown
CategoryWinnerWhy
GrowthTOI logoTOI27.8% revenue growth vs CAH's -1.9%
ValueOPCH logoOPCHLower P/E (11.3x vs 13.8x)
Quality / MarginsOPCH logoOPCH3.6% margin vs TOI's -8.0%
Stability / SafetyCVS logoCVSBeta 0.19 vs TOI's 1.95
DividendsCVS logoCVS2.6% yield, vs CAH's 0.9%, (2 stocks pay no dividend)
Momentum (1Y)TOI logoTOI+100.4% vs OPCH's -34.9%
Efficiency (ROA)OPCH logoOPCH6.0% ROA vs TOI's -26.5%, ROIC 15.3% vs -41.2%

TOI vs OPCH vs MCK vs CAH vs CVS — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

Discover the Biotech & Healthcare Stocks Theme

These companies are key players in the Biotech & Healthcare Stocks ecosystem. See how they stack up against the rest of the sector.

Explore Theme
TOIThe Oncology Institute, Inc.
FY 2025
Health Care, Patient Service
49.5%$229M
Fee For Service
32.1%$149M
Capitated Revenue
17.4%$80M
Clinical Research Trials And Other Revenue
1.0%$5M
OPCHOption Care Health, Inc.
FY 2025
Reportable Segment
100.0%$5.6B
MCKMcKesson Corporation
FY 2026
North American Pharmaceutical Segment
83.4%$336.7B
Oncology And Multispecialty Segment
12.0%$48.4B
Medical-Surgical Solutions Segment
2.9%$11.5B
Prescription Technology Solutions Segment
1.4%$5.8B
Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment
0.3%$1.0B
CAHCardinal Health, Inc.
FY 2025
Pharmaceutical Member
91.9%$204.6B
GMPD
5.7%$12.6B
Other Operating Segment
2.4%$5.4B
CVSCVS Health Corporation
FY 2025
Pharmacy Revenue
58.9%$229.0B
Premiums
34.6%$134.8B
Front Store Revenue
5.5%$21.5B
Product and Service, Other
1.0%$3.9B

TOI vs OPCH vs MCK vs CAH vs CVS — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLOPCHLAGGINGCVS

Income & Cash Flow (Last 12 Months)

OPCH leads this category, winning 4 of 6 comparable metrics.

CVS is the larger business by revenue, generating $407.9B annually — 747.4x TOI's $546M. OPCH is the more profitable business, keeping 3.6% of every revenue dollar as net income compared to TOI's -8.0%. On growth, TOI holds the edge at +41.2% YoY revenue growth, suggesting stronger near-term business momentum.

MetricTOI logoTOIThe Oncology Inst…OPCH logoOPCHOption Care Healt…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …CVS logoCVSCVS Health Corpor…
RevenueTrailing 12 months$546M$5.7B$403.4B$250.5B$407.9B
EBITDAEarnings before interest/tax-$26M$406M$7.1B$3.2B$10.5B
Net IncomeAfter-tax profit-$44M$206M$4.8B$1.6B$2.9B
Free Cash FlowCash after capex-$26M$244M$5.9B$4.4B$7.4B
Gross MarginGross profit ÷ Revenue+14.8%+18.0%+3.6%+3.7%+13.9%
Operating MarginEBIT ÷ Revenue-6.0%+5.9%+1.6%+0.9%+1.5%
Net MarginNet income ÷ Revenue-8.0%+3.6%+1.2%+0.6%+0.7%
FCF MarginFCF ÷ Revenue-4.7%+4.3%+1.5%+1.8%+1.8%
Rev. Growth (YoY)Latest quarter vs prior year+41.2%+1.3%+6.0%+11.0%+6.2%
EPS Growth (YoY)Latest quarter vs prior year+90.5%+3.6%+37.0%-19.5%+63.1%
OPCH leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

OPCH leads this category, winning 3 of 6 comparable metrics.

At 16.3x trailing earnings, OPCH trades at a 78% valuation discount to CVS's 73.4x P/E. On an enterprise value basis, OPCH's 7.4x EV/EBITDA is more attractive than CAH's 19.0x.

MetricTOI logoTOIThe Oncology Inst…OPCH logoOPCHOption Care Healt…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …CVS logoCVSCVS Health Corpor…
Market CapShares × price$5.4B$3.2B$94.2B$52.7B$130.1B
Enterprise ValueMkt cap + debt − cash$5.5B$3.0B$98.9B$58.1B$215.2B
Trailing P/EPrice ÷ TTM EPS-9.83x16.35x20.43x34.71x73.35x
Forward P/EPrice ÷ next-FY EPS est.11.31x17.72x20.79x13.78x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple7.38x13.77x18.97x14.35x
Price / SalesMarket cap ÷ Revenue10.75x0.57x0.23x0.24x0.32x
Price / BookPrice ÷ Book value/share2.56x1.72x
Price / FCFMarket cap ÷ FCF12.57x16.48x28.47x16.66x
OPCH leads this category, winning 3 of 6 comparable metrics.

Profitability & Efficiency

OPCH leads this category, winning 4 of 8 comparable metrics.

OPCH delivers a 15.3% return on equity — every $100 of shareholder capital generates $15 in annual profit, vs $4 for CVS. On the Piotroski fundamental quality scale (0–9), MCK scores 7/9 vs TOI's 4/9, reflecting strong financial health.

MetricTOI logoTOIThe Oncology Inst…OPCH logoOPCHOption Care Healt…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …CVS logoCVSCVS Health Corpor…
ROE (TTM)Return on equity+15.3%+3.9%
ROA (TTM)Return on assets-26.5%+6.0%+5.7%+2.8%+1.1%
ROICReturn on invested capital-41.2%+15.3%+2.5%+33.8%+5.0%
ROCEReturn on capital employed-33.7%+12.8%+44.8%+19.2%+6.1%
Piotroski ScoreFundamental quality 0–945765
Debt / EquityFinancial leverage1.24x
Net DebtTotal debt minus cash$70M-$233M$4.6B$5.5B$85.1B
Cash & Equiv.Liquid assets$34M$233M$4.0B$3.9B$8.5B
Total DebtShort + long-term debt$104M$0$8.6B$9.3B$93.6B
Interest CoverageEBIT ÷ Interest expense-4.96x5.50x51.78x6.38x2.11x
OPCH leads this category, winning 4 of 8 comparable metrics.

Total Returns (Dividends Reinvested)

TOI leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in MCK five years ago would be worth $41,299 today (with dividends reinvested), compared to $5,257 for TOI. Over the past 12 months, TOI leads with a +100.4% total return vs OPCH's -34.9%. The 3-year compound annual growth rate (CAGR) favors TOI at 111.1% vs OPCH's -11.6% — a key indicator of consistent wealth creation.

MetricTOI logoTOIThe Oncology Inst…OPCH logoOPCHOption Care Healt…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …CVS logoCVSCVS Health Corpor…
YTD ReturnYear-to-date+44.7%-35.6%-4.6%+9.3%+28.9%
1-Year ReturnPast 12 months+100.4%-34.9%+7.7%+40.7%+57.7%
3-Year ReturnCumulative with dividends+841.3%-30.9%+100.5%+163.7%+53.6%
5-Year ReturnCumulative with dividends-47.4%+1.1%+313.0%+300.9%+35.0%
10-Year ReturnCumulative with dividends-45.3%+127.6%+337.8%+211.1%+29.5%
CAGR (3Y)Annualised 3-year return+111.1%-11.6%+26.1%+38.2%+15.4%
TOI leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — MCK and CVS each lead in 1 of 2 comparable metrics.

MCK is the less volatile stock with a -0.10 beta — it tends to amplify market swings less than TOI's 1.95 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CVS currently trades 99.2% from its 52-week high vs OPCH's 56.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricTOI logoTOIThe Oncology Inst…OPCH logoOPCHOption Care Healt…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …CVS logoCVSCVS Health Corpor…
Beta (5Y)Sensitivity to S&P 5001.95x0.29x-0.10x-0.07x0.19x
52-Week HighHighest price in past year$5.58$36.80$999.00$233.60$102.77
52-Week LowLowest price in past year$2.02$18.01$637.00$137.75$58.50
% of 52W HighCurrent price vs 52-week peak+95.2%+56.4%+78.5%+95.8%+99.2%
RSI (14)Momentum oscillator 0–10065.344.155.574.472.6
Avg Volume (50D)Average daily shares traded1.6M3.2M879K1.9M7.6M
Evenly matched — MCK and CVS each lead in 1 of 2 comparable metrics.

Analyst Outlook

Evenly matched — CAH and CVS each lead in 1 of 2 comparable metrics.

Analyst consensus: TOI as "Buy", OPCH as "Buy", MCK as "Buy", CAH as "Buy", CVS as "Buy". Consensus price targets imply 50.7% upside for TOI (target: $8) vs 1.6% for CVS (target: $104). For income investors, CVS offers the higher dividend yield at 2.62% vs MCK's 0.39%.

MetricTOI logoTOIThe Oncology Inst…OPCH logoOPCHOption Care Healt…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …CVS logoCVSCVS Health Corpor…
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuyBuy
Price TargetConsensus 12-month target$8.00$31.22$994.86$253.38$103.64
# AnalystsCovering analysts514313341
Dividend YieldAnnual dividend ÷ price+0.4%+0.9%+2.6%
Dividend StreakConsecutive years of raises118400
Dividend / ShareAnnual DPS$3.07$2.04$2.67
Buyback YieldShare repurchases ÷ mkt cap0.0%+9.5%+5.0%+1.5%0.0%
Evenly matched — CAH and CVS each lead in 1 of 2 comparable metrics.
Key Takeaway

OPCH leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). TOI leads in 1 (Total Returns). 2 tied.

Best OverallOption Care Health, Inc. (OPCH)Leads 3 of 6 categories
Loading custom metrics...

TOI vs OPCH vs MCK vs CAH vs CVS: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is TOI or OPCH or MCK or CAH or CVS a better buy right now?

For growth investors, The Oncology Institute, Inc.

(TOI) is the stronger pick with 27. 8% revenue growth year-over-year, versus -1. 9% for Cardinal Health, Inc. (CAH). Option Care Health, Inc. (OPCH) offers the better valuation at 16. 3x trailing P/E (11. 3x forward), making it the more compelling value choice. Analysts rate The Oncology Institute, Inc. (TOI) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — TOI or OPCH or MCK or CAH or CVS?

On trailing P/E, Option Care Health, Inc.

(OPCH) is the cheapest at 16. 3x versus CVS Health Corporation at 73. 4x. On forward P/E, Option Care Health, Inc. is actually cheaper at 11. 3x.

03

Which is the better long-term investment — TOI or OPCH or MCK or CAH or CVS?

Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +313.

0%, compared to -47. 4% for The Oncology Institute, Inc. (TOI). Over 10 years, the gap is even starker: MCK returned +337. 8% versus TOI's -45. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — TOI or OPCH or MCK or CAH or CVS?

By beta (market sensitivity over 5 years), McKesson Corporation (MCK) is the lower-risk stock at -0.

10β versus The Oncology Institute, Inc. 's 1. 95β — meaning TOI is approximately -2003% more volatile than MCK relative to the S&P 500.

05

Which is growing faster — TOI or OPCH or MCK or CAH or CVS?

By revenue growth (latest reported year), The Oncology Institute, Inc.

(TOI) is pulling ahead at 27. 8% versus -1. 9% for Cardinal Health, Inc. (CAH). On earnings-per-share growth, the picture is similar: Cardinal Health, Inc. grew EPS 87. 0% year-over-year, compared to -62. 0% for CVS Health Corporation. Over a 3-year CAGR, TOI leads at 25. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — TOI or OPCH or MCK or CAH or CVS?

Option Care Health, Inc.

(OPCH) is the more profitable company, earning 3. 7% net margin versus -12. 1% for The Oncology Institute, Inc. — meaning it keeps 3. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: OPCH leads at 6. 0% versus -7. 2% for TOI. At the gross margin level — before operating expenses — OPCH leads at 18. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is TOI or OPCH or MCK or CAH or CVS more undervalued right now?

On forward earnings alone, Option Care Health, Inc.

(OPCH) trades at 11. 3x forward P/E versus 20. 8x for Cardinal Health, Inc. — 9. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TOI: 50. 7% to $8. 00.

08

Which pays a better dividend — TOI or OPCH or MCK or CAH or CVS?

In this comparison, CVS (2.

6% yield), CAH (0. 9% yield), MCK (0. 4% yield) pay a dividend. TOI, OPCH do not pay a meaningful dividend and should not be held primarily for income.

09

Is TOI or OPCH or MCK or CAH or CVS better for a retirement portfolio?

For long-horizon retirement investors, Cardinal Health, Inc.

(CAH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 07), 0. 9% yield, +211. 1% 10Y return). The Oncology Institute, Inc. (TOI) carries a higher beta of 1. 95 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CAH: +211. 1%, TOI: -45. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between TOI and OPCH and MCK and CAH and CVS?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: TOI is a small-cap high-growth stock; OPCH is a small-cap deep-value stock; MCK is a mid-cap quality compounder stock; CAH is a mid-cap quality compounder stock; CVS is a mid-cap quality compounder stock. CAH, CVS pay a dividend while TOI, OPCH, MCK do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.